Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | CD274 positive |
| Therapy | Cisplatin + Paclitaxel + Tislelizumab |
| Indication/Tumor Type | esophagus squamous cell carcinoma |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| CD274 positive | esophagus squamous cell carcinoma | sensitive | Cisplatin + Paclitaxel + Tislelizumab | Guideline | Actionable | Tevimbra (tislelizumab) in combination with Taxol (paclitaxel) and Platinol (cisplatin) is included in guidelines as preferred systemic therapy for patients with unresectable locally advanced, recurrent, or metastatic esophageal squamous cell carcinoma expressing PD-L1 (CD274) with CPS >/= 1 (NCCN.org). | detail... |
| PubMed Id | Reference Title | Details |
|---|---|---|
| NCCN.org | Full reference... |